Gadoversetamide

Gadoversetamide
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	Intravenous
ATC code	V08CA06 (WHO) ;
Pharmacokinetic data
Protein binding	Nil
Metabolism	Nil
Elimination half-life	80 to 120 minutes
Excretion	Renal
Identifiers
CAS Number	131069-91-5 ;
PubChem CID	6435809;
DrugBank	DB00538 ;
ChemSpider	392041 ;
UNII	RLM74T3Z9D;
KEGG	D01646 ;
ChEMBL	ChEMBL1200457 ;
CompTox Dashboard (EPA)	DTXSID10156865 ;
Chemical and physical data
Formula	C20H34GdN5O10
Molar mass	661.77 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Gd+3].O=C(NCCOC)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(=O)NCCOC)CC([O-])=O;
	InChI InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3 ; Key:HBEAOBRDTOXWRZ-UHFFFAOYSA-K ;
	(what is this?) (verify)

Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver.^[1] It is marketed under the trade name OptiMARK.

Notes

^ "Gadoversetamide Drug Information". Drugs.com. 2000-03-20. Retrieved 2007-03-23.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.